Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 6
2004 19
2005 17
2006 23
2007 28
2008 13
2009 21
2010 15
2011 18
2012 15
2013 8
2014 11
2015 10
2016 11
2017 8
2018 7
2019 7
2020 13
2021 6
2022 9
2023 8
2024 2
2025 7
2026 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Results by year

Filters applied: . Clear all
Page 1
Hypereosinophilia: clinical and therapeutic approach in 2025.
Taurisano G, Ruffi MC, Canalis S, Costanzo GAML. Taurisano G, et al. Curr Opin Allergy Clin Immunol. 2025 Aug 1;25(4):258-268. doi: 10.1097/ACI.0000000000001078. Epub 2025 May 21. Curr Opin Allergy Clin Immunol. 2025. PMID: 40396537 Free PMC article. Review.
Clinical manifestations range from asymptomatic eosinophilia to life-threatening complications involving the skin, lungs, gastrointestinal tract, heart, and nervous system. Corticosteroids remain the first-line treatment across most subtypes. Imatinib has shown high …
Clinical manifestations range from asymptomatic eosinophilia to life-threatening complications involving the skin, lungs, gastrointes …
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuation.
Metzgeroth G, Schwaab J, Naumann N, Jawhar M, Haferlach T, Fabarius A, Hochhaus A, Hofmann WK, Cross NCP, Reiter A. Metzgeroth G, et al. Blood Adv. 2020 Feb 11;4(3):440-443. doi: 10.1182/bloodadvances.2019001111. Blood Adv. 2020. PMID: 31995156 Free PMC article.
FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) are exquisitely sensitive to imatinib. ...Our data demonstrate that imatinib can be safely stopped in FIP1L1-PDGFRA-positive MLN-eo because of a high trea …
FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia (MLN-eo) are exquisitely sensitive to imatinib …
[Hematological hypereosinophilia].
Ghariani I, Mahmoud O, Hamzaoui S, Braham N, Bekir L. Ghariani I, et al. Ann Biol Clin (Paris). 2022 Jul 1;80(4):355-362. doi: 10.1684/abc.2022.1731. Ann Biol Clin (Paris). 2022. PMID: 36099347 Free article. French.
Several other quantitative and qualitative abnormalities of the blood picture were reported. Identification of the FIP1L1-PDGFRA fusion gene by molecular biology (RT-PCR) was positive in two patients. Imatinib was the main treatment for clonal forms. ...
Several other quantitative and qualitative abnormalities of the blood picture were reported. Identification of the FIP1L1-PDGFRA …
Successful imatinib treatment of cardiac involvement of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia followed by severe hepatotoxicity.
Arai A, Yan W, Wakabayashi S, Hayashi S, Inazawa J, Miura O. Arai A, et al. Int J Hematol. 2007 Oct;86(3):233-7. doi: 10.1532/IJH97.07032. Int J Hematol. 2007. PMID: 17988989 Review.
Imatinib is highly effective for the treatment of chronic eosinophilic leukemia (CEL) caused by the FIP1L1-PDGFRA fusion gene. ...Fortunately, the FIP1L1-PDGFRA fusion transcript had become undetectable, and imatinib treatment was stopped …
Imatinib is highly effective for the treatment of chronic eosinophilic leukemia (CEL) caused by the FIP1L1-PDGFRA fusio …
Hypereosinophilic syndromes.
Roufosse FE, Goldman M, Cogan E. Roufosse FE, et al. Orphanet J Rare Dis. 2007 Sep 11;2:37. doi: 10.1186/1750-1172-2-37. Orphanet J Rare Dis. 2007. PMID: 17848188 Free PMC article. Review.
Recent advances in underlying pathogenesis have established that hypereosinophilia may be due either to primitive involvement of myeloid cells, essentially due to occurrence of an interstitial chromosomal deletion on 4q12 leading to creation of the FIP1L1-PDGFRA fus …
Recent advances in underlying pathogenesis have established that hypereosinophilia may be due either to primitive involvement of myeloid cel …
FIP1L1-PDGFRA molecular analysis in the differential diagnosis of eosinophilia.
Loules G, Kalala F, Giannakoulas N, Papadakis E, Matsouka P, Speletas M. Loules G, et al. BMC Blood Disord. 2009 Feb 2;9:1. doi: 10.1186/1471-2326-9-1. BMC Blood Disord. 2009. PMID: 19187542 Free PMC article.
BACKGROUND: Primary eosinophlia associated with the FIP1L1-PDGFRA rearrangement represents a subset of chronic eosinophilic leukaemia (CEL) and affected patients are very sensitive to imatinib treatment. This study was undertaken in order to examine the preva …
BACKGROUND: Primary eosinophlia associated with the FIP1L1-PDGFRA rearrangement represents a subset of chronic eosinophilic le …
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Ogbogu PU, Bochner BS, Butterfield JH, Gleich GJ, Huss-Marp J, Kahn JE, Leiferman KM, Nutman TB, Pfab F, Ring J, Rothenberg ME, Roufosse F, Sajous MH, Sheikh J, Simon D, Simon HU, Stein ML, Wardlaw A, Weller PF, Klion AD. Ogbogu PU, et al. J Allergy Clin Immunol. 2009 Dec;124(6):1319-25.e3. doi: 10.1016/j.jaci.2009.09.022. J Allergy Clin Immunol. 2009. PMID: 19910029 Free PMC article.
RESULTS: Eighteen of 161 patients (11%) tested were Fip1-like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) mutation-positive, and 29 of 168 patients tested (17%) had a demonstrable aberrant or clonal T-cell population. ...Hydroxyurea and IFN-alpha …
RESULTS: Eighteen of 161 patients (11%) tested were Fip1-like 1-platelet-derived growth factor receptor alpha (FIP1L1-PDGFRA) …
Lymphomatoid papulosis associated with myeloid neoplasm with eosinophilia and FIP1L1::PDGFRA rearrangement: Successful imatinib treatment in two cases.
Bellani V, Croci GA, Bucelli C, Maronese CA, Alberti S, Iurlo A, Cattaneo D. Bellani V, et al. J Dermatol. 2023 Oct;50(10):1330-1334. doi: 10.1111/1346-8138.16836. Epub 2023 May 30. J Dermatol. 2023. PMID: 37248740 Free article.
Among eosinophilic disorders, the subtype identified as myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions has aroused particular interest due to its excellent response to tyrosine kinase inhibitors, including imatinib. Here, we described t …
Among eosinophilic disorders, the subtype identified as myeloid/lymphoid neoplasm with eosinophilia and tyrosine kinase gene fusions …
Hypereosinophilic disorders.
Ogbogu PU, Klion AD. Ogbogu PU, et al. J Allergy Clin Immunol Pract. 2015 Mar-Apr;3(2):304-5; quiz 306. doi: 10.1016/j.jaip.2014.09.024. J Allergy Clin Immunol Pract. 2015. PMID: 25754721 Free PMC article. No abstract available.
FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia.
Pardanani A, Brockman SR, Paternoster SF, Flynn HC, Ketterling RP, Lasho TL, Ho CL, Li CY, Dewald GW, Tefferi A. Pardanani A, et al. Blood. 2004 Nov 15;104(10):3038-45. doi: 10.1182/blood-2004-03-0787. Epub 2004 Jul 29. Blood. 2004. PMID: 15284118 Free article.
A fluorescence in situ hybridization (FISH)-based strategy was used to detect FIP1L1-PDGFRA in bone marrow cells. None of 8 patients with reactive eosinophilia displayed the abnormality, whereas the incidence of FIP1L1-PDGFRA in the remaining 81 …
A fluorescence in situ hybridization (FISH)-based strategy was used to detect FIP1L1-PDGFRA in bone marrow cells. None of 8 pa …
256 results